Pharmasset Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Princeton NJ United States (1998)
Status: Acquired by Gilead Sciences (2012)

Organization Overview

First Clinical Trial
2002
NCT00040300
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 3)

HIV Infections (Phase 2)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 9